Address
Muenchensteinerstrasse 38
Basel, 4002
Switzerland
Phone
41 61 316 81 11
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
17995
First IPO Date
November 01, 1999
| Name | Title | Pay | Year Born |
| Wolfgang Wienand | Chief Executive Officer | 2.17M | 1972 |
| Nicoleta Baumgartner | Chief Human Resources Officer | 0 | 1971 |
| Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility | 0 | N/A |
| Andreas Bohrer | Chief Legal & Corporate Affairs Officer | 0 | N/A |
| Victoria Morgan | Head of External Communications | 0 | N/A |
| Christian Seufert | President of Capsules & Health Ingredients Division | 0 | 1975 |
| Daniel Buchta | Head of Investor Relations | 0 | N/A |
| Gordon Bates | President of Small Molecules Division | 0 | 1965 |
| Jason Berndt | Executive Vice President & Head of Group Operations | 0 | N/A |
| Jean-Christophe Hyvert | President of Biologics Division | 0 | 1972 |
| Philippe Deecke | Chief Financial Officer | 0 | N/A |
| Jennifer Clancy | Senior Director of Global Marketing | 0 | N/A |
| Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability | 0 | N/A |
Lonza Group AG is a Swiss-based multinational corporation that provides a diverse range of products and services globally to the pharmaceutical, biotechnology, and nutrition industries. Its comprehensive operations are structured into four key business segments. The Biologics division specializes in contract development and manufacturing for biopharmaceutical compounds. The Small Molecules segment offers integrated services for the development and production of small molecule drug substances and their intermediate components. The Cell and Gene division is at the forefront of industrializing manufacturing processes and production for advanced cell and gene therapies. This unit also offers contract development and manufacturing services for various cell therapies (allogeneic, autologous, exosome-based) and viral vector gene therapies. Additionally, it supplies specialized raw materials and technological solutions vital for cell and gene therapy, injectable drugs, vaccines, and broader bio-manufacturing applications. Finally, the Capsules and Health Ingredients division delivers encapsulation solutions, dosage forms, and health-enhancing ingredients to both pharmaceutical and nutraceutical customers. Founded in 1897, Lonza Group AG maintains its headquarters in Basel, Switzerland.